3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
14
Brain Neoplasms
12
Glioma
11
Astrocytoma
9
Meningioma
7
Central Nervous System Neoplasms
7
Gliosarcoma
6
Diffuse Intrinsic Pontine Glioma
6
Recurrence
4
Neurofibromatosis 2
4
Tuberous Sclerosis
3
Pheochromocytoma
3
Paraganglioma
3
Neuroma, Acoustic
3
Rhabdomyosarcoma
2
Oligodendroglioma
2
Neurofibromatosis 1
2
Neuroendocrine Tumors
2
Neoplasms
2
Hereditary Sensory and Autonomic Neuropathies
2
von Hippel-Lindau Disease
1
Zollinger-Ellison Syndrome
1
Vestibulocochlear Nerve Diseases
1
Tuberous Sclerosis 2
1
Tongue Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Seizures
1
Sarcoma
1
Salivary Gland Neoplasms
1
Interventions
Levetiracetam
6
perampanel
2
Tranexamic Acid
2
Standard of Care
2
ziprasidone
1
Zolpidem
1
Warfarin
1
Vecuronium Bromide
1
Vancomycin
1
Tobramycin
1
Temozolomide
1
Spironolactone
1
Sodium Chloride
1
Sevelamer
1
Saline Solution
1
Rocuronium
1
Pregabalin
1
Piperacillin, Tazobactam Drug Combination
1
Pentobarbital
1
Oxycodone
1
Nifedipine
1
Nafcillin
1
Molindone
1
Methylprednisolone
1
Mental Status and Dementia Tests
1
Magnetic Resonance Spectroscopy
1
Magnesium Sulfate
1
Lurasidone Hydrochloride
1
Labetalol
1
Haloperidol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Seizures
×
Everolimus
×
CNS
×
Clear all
NCT00790400
2017-02-17
EXIST-2
Novartis
Phase 3
Completed
118 enrolled
15 charts